Stoke Therapeutics (STOK) Operating Income (2018 - 2026)

Stoke Therapeutics' Operating Income history runs 9 years deep, the most recent figure standing at -$53.4 million for Q1 2026.

• On a quarterly basis, Operating Income fell 148.02% year-over-year to -$53.4 million in Q1 2026; TTM through Mar 2026 was -$185.2 million, a 584.41% decrease from a year earlier, with the FY2025 full-year figure at -$20.6 million, up 79.69% from the prior year.
• Operating Income grew to -$53.4 million in Q1 2026 per STOK's latest filing, from -$61.4 million in the prior quarter.
• Across five years, Operating Income topped out at $111.2 million in Q1 2025 and bottomed at -$61.4 million in Q4 2025.
• The 5-year median for Operating Income is -$27.3 million (2025), against an average of -$23.2 million.
• Biggest YoY gain for Operating Income was 492.08% in 2025; the steepest drop was 350.0% in 2025.
• Year by year, Operating Income stood at -$27.2 million in 2022, then dropped by 8.87% to -$29.6 million in 2023, then jumped by 53.85% to -$13.7 million in 2024, then slumped by 350.0% to -$61.4 million in 2025, then grew by 13.06% to -$53.4 million in 2026.
• Per Business Quant, the three latest STOK Operating Income figures stand at -$53.4 million (Q1 2026), -$61.4 million (Q4 2025), and -$43.1 million (Q3 2025).